• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

106.76 -5.79 (-5.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
December 11, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
December 10, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
November 10, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
November 07, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
November 05, 2025
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
November 04, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
August 27, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
August 20, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
August 05, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
July 22, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
July 12, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
July 10, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 09, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
July 09, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
July 08, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
June 25, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
May 14, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
May 07, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
May 06, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
April 23, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
April 07, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
April 06, 2025
Company to host conference call on April 7 at 8 a.m. ET 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
March 20, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
March 19, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
March 18, 2025
New registry study to focus on impact of fatigue in people with craniopharyngioma 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
February 26, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
February 13, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
February 05, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
January 10, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap